Cargando…

Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome

BACKGROUND AND OBJECTIVE: The long-QT syndrome (LQTS) is associated with premature sudden cardiac deaths affecting whole families and is caused by mutations in genes encoding for cardiac proteins. When the same mutation is found in different families (recurrent mutations), this may imply either a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofman, N., Jongbloed, R., Postema, P. G., Nannenberg, E., Alders, M., Wilde, A. A. M.
Formato: Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021187/
https://www.ncbi.nlm.nih.gov/pubmed/21350584
http://dx.doi.org/10.1007/s12471-010-0046-4
_version_ 1782196352469434368
author Hofman, N.
Jongbloed, R.
Postema, P. G.
Nannenberg, E.
Alders, M.
Wilde, A. A. M.
author_facet Hofman, N.
Jongbloed, R.
Postema, P. G.
Nannenberg, E.
Alders, M.
Wilde, A. A. M.
author_sort Hofman, N.
collection PubMed
description BACKGROUND AND OBJECTIVE: The long-QT syndrome (LQTS) is associated with premature sudden cardiac deaths affecting whole families and is caused by mutations in genes encoding for cardiac proteins. When the same mutation is found in different families (recurrent mutations), this may imply either a common ancestor (founder) or multiple de novo mutations. We aimed to review recurrent mutations in patients with LQTS. METHODS: By use of our databases, we investigated the number of mutations that were found recurrently (at least three times) in LQT type 1–3 patients in the Netherlands. We studied familial links in the apparently unrelated probands, and we visualised the geographical distribution of these probands. Our results were compared with published literature of founder effects in LQTS outside the Netherlands. RESULTS: We counted 14 recurrent LQT mutations in the Netherlands. There are 326 identified carriers of one of these mutations. For three of these mutations, familial links were found between apparently unrelated probands. CONCLUSION: Whereas true LQT founder mutations are described elsewhere in the world, we cannot yet demonstrate a real founder effect of these recurrent mutations in the Netherlands. Further studies on the prevalence of these mutations are indicated, and haplotype-sharing of the mutation carriers is pertinent to provide more evidence for founder mutation-based LQTS pathology in our country.
format Text
id pubmed-3021187
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Bohn Stafleu van Loghum
record_format MEDLINE/PubMed
spelling pubmed-30211872011-02-22 Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome Hofman, N. Jongbloed, R. Postema, P. G. Nannenberg, E. Alders, M. Wilde, A. A. M. Neth Heart J Original Article BACKGROUND AND OBJECTIVE: The long-QT syndrome (LQTS) is associated with premature sudden cardiac deaths affecting whole families and is caused by mutations in genes encoding for cardiac proteins. When the same mutation is found in different families (recurrent mutations), this may imply either a common ancestor (founder) or multiple de novo mutations. We aimed to review recurrent mutations in patients with LQTS. METHODS: By use of our databases, we investigated the number of mutations that were found recurrently (at least three times) in LQT type 1–3 patients in the Netherlands. We studied familial links in the apparently unrelated probands, and we visualised the geographical distribution of these probands. Our results were compared with published literature of founder effects in LQTS outside the Netherlands. RESULTS: We counted 14 recurrent LQT mutations in the Netherlands. There are 326 identified carriers of one of these mutations. For three of these mutations, familial links were found between apparently unrelated probands. CONCLUSION: Whereas true LQT founder mutations are described elsewhere in the world, we cannot yet demonstrate a real founder effect of these recurrent mutations in the Netherlands. Further studies on the prevalence of these mutations are indicated, and haplotype-sharing of the mutation carriers is pertinent to provide more evidence for founder mutation-based LQTS pathology in our country. Bohn Stafleu van Loghum 2010-12-17 2011-01 /pmc/articles/PMC3021187/ /pubmed/21350584 http://dx.doi.org/10.1007/s12471-010-0046-4 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Hofman, N.
Jongbloed, R.
Postema, P. G.
Nannenberg, E.
Alders, M.
Wilde, A. A. M.
Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title_full Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title_fullStr Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title_full_unstemmed Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title_short Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
title_sort recurrent and founder mutations in the netherlands: the long-qt syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021187/
https://www.ncbi.nlm.nih.gov/pubmed/21350584
http://dx.doi.org/10.1007/s12471-010-0046-4
work_keys_str_mv AT hofmann recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome
AT jongbloedr recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome
AT postemapg recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome
AT nannenberge recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome
AT aldersm recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome
AT wildeaam recurrentandfoundermutationsinthenetherlandsthelongqtsyndrome